IRIS UniCatt

Di Giambenedetto, Simona
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.142
EU - Europa 10.532
AS - Asia 9.492
SA - Sud America 2.018
Continente sconosciuto - Info sul continente non disponibili 467
AF - Africa 306
OC - Oceania 43
AN - Antartide 1
Totale 38.001
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.652
SG - Singapore 4.355
DE - Germania 2.568
CN - Cina 2.097
BR - Brasile 1.646
SE - Svezia 1.572
IT - Italia 1.401
FR - Francia 1.271
PL - Polonia 830
VN - Vietnam 806
UA - Ucraina 639
IE - Irlanda 477
GB - Regno Unito 470
IN - India 419
NL - Olanda 416
ID - Indonesia 314
FI - Finlandia 294
BD - Bangladesh 266
CA - Canada 245
JP - Giappone 225
HK - Hong Kong 196
RU - Federazione Russa 192
AR - Argentina 156
TR - Turchia 147
MX - Messico 126
IQ - Iraq 102
ZA - Sudafrica 86
ES - Italia 73
PK - Pakistan 72
BE - Belgio 63
AT - Austria 62
IR - Iran 57
SA - Arabia Saudita 51
KR - Corea 45
MA - Marocco 44
EC - Ecuador 41
VE - Venezuela 41
CO - Colombia 36
LT - Lituania 36
PH - Filippine 36
UZ - Uzbekistan 36
AU - Australia 34
KE - Kenya 31
CH - Svizzera 30
CL - Cile 30
EG - Egitto 30
JO - Giordania 28
JM - Giamaica 26
TN - Tunisia 26
CI - Costa d'Avorio 25
PY - Paraguay 24
MY - Malesia 23
KZ - Kazakistan 22
AZ - Azerbaigian 20
IL - Israele 19
AE - Emirati Arabi Uniti 17
PE - Perù 17
CR - Costa Rica 15
CZ - Repubblica Ceca 14
OM - Oman 14
GR - Grecia 13
NP - Nepal 13
TW - Taiwan 13
UY - Uruguay 13
LB - Libano 12
PA - Panama 12
PT - Portogallo 12
RO - Romania 12
AL - Albania 11
BO - Bolivia 11
CM - Camerun 11
DZ - Algeria 11
HN - Honduras 11
NG - Nigeria 10
TH - Thailandia 10
DO - Repubblica Dominicana 9
EU - Europa 9
MD - Moldavia 9
PS - Palestinian Territory 9
BH - Bahrain 8
ET - Etiopia 8
KG - Kirghizistan 8
NI - Nicaragua 8
NZ - Nuova Zelanda 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
LV - Lettonia 7
PR - Porto Rico 7
QA - Qatar 7
RS - Serbia 7
DK - Danimarca 6
LK - Sri Lanka 6
NO - Norvegia 6
BY - Bielorussia 5
CY - Cipro 5
GT - Guatemala 5
HR - Croazia 5
LA - Repubblica Popolare Democratica del Laos 5
BA - Bosnia-Erzegovina 4
GE - Georgia 4
Totale 37.451
Salva come PNG Salva come JPEG
Città #
Singapore 2.249
Chandler 1.920
Ashburn 1.649
San Jose 1.260
Kraków 599
New York 583
Dublin 469
Jacksonville 424
Beijing 411
San Mateo 382
Amsterdam 381
Los Angeles 357
Milan 329
Jakarta 280
Lauterbourg 277
Ho Chi Minh City 271
Rome 250
Nanjing 227
Wilmington 221
Warsaw 208
Boston 206
Tokyo 198
Hanoi 196
Hefei 190
Ann Arbor 186
Houston 185
The Dalles 179
Hong Kong 167
Dearborn 165
Dallas 160
São Paulo 144
Chicago 137
Frankfurt am Main 136
Princeton 127
Cattolica 126
Lawrence 122
Santa Clara 114
Nürnberg 110
Munich 108
Helsinki 107
Moscow 107
Woodbridge 107
Redwood City 104
Nanchang 95
Seattle 95
St Louis 95
Orem 86
Atlanta 85
Buffalo 84
Marseille 83
Boardman 79
Redmond 75
Montreal 71
Brooklyn 67
Izmir 67
London 67
Brussels 60
Fairfield 60
Lancaster 60
Nuremberg 60
Bremen 55
Düsseldorf 55
Toronto 55
Paris 54
Shenyang 52
Rio de Janeiro 51
Mountain View 50
Johannesburg 49
Denver 48
Kent 47
Pune 47
Norwalk 45
Poplar 45
Changsha 43
Chennai 43
Memphis 43
Kunming 42
Guangzhou 41
Tukwila 41
Augusta 40
Shanghai 40
Council Bluffs 39
Haiphong 39
Vienna 39
Da Nang 37
Hebei 37
Phoenix 37
Tianjin 37
University Park 37
Washington 37
Belo Horizonte 35
Mexico City 35
Ottawa 35
Hangzhou 34
Turku 34
Verona 34
Seoul 33
Stockholm 33
Baghdad 30
Manchester 30
Totale 19.075
Salva come PNG Salva come JPEG
Nome #
Functional associations between polymorphic regions of the human 3'IgH locus and COVID-19 disease 855
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 529
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 387
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 321
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 270
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 261
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 256
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 235
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV 235
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 232
Psychological distress during the initial stage of the COVID-19 pandemic in an italian population living with HIV: An online survey 227
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 224
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 221
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 220
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 215
Impact of the COVID-19 Pandemic on Health Care Is Negatively Associated With Psychosocial Well-Being in an Italian Cohort of People Living With HIV 213
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 212
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 210
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 210
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 210
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 208
Use of telehealth for HIV care in Italy: Are doctors and patients on the same page? A cross-sectional study 206
Validation of an UPLC-MS/MS Method for Quantitative Analysis of Raltegravir in Human Plasma Samples 205
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study 201
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 199
Assessment of neurological manifestations in hospitalized patients with COVID-19 199
Residual respiratory impairment after COVID-19 pneumonia 198
The association between stigma and wellbeing in an Italian cohort of PLWH: The role of social support and personal factors 198
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 197
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 197
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 197
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 197
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice 196
Variability of raltegravir plasma levels in the clinical setting 195
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 194
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 193
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 192
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 189
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 189
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 187
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 185
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 185
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 183
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 183
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 182
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 180
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 179
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 179
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 179
Cardiovascular Disease Risk in a Cohort of Virologically Suppressed People Living with HIV Switching to Doravirine: Preliminary Data from the Real Life 177
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 177
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 173
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 172
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 171
Shall we dance? Extending tango's results to clinical practice 169
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 168
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 168
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 166
Cognitive reserve and neuropsychological functioning in older HIV-infected people 165
Mortality in patients with early- or late-onset candidaemia 164
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 161
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 161
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 161
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 159
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 159
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 159
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients 159
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 158
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 158
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 157
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 157
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 156
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 156
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 154
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 154
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 154
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report 154
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice 152
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 151
Effect of aging and human immunodeficiency virus infection on cognitive abilities 151
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 151
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 150
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 150
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 149
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 149
HIV-Related Internalized Stigma and Patient Health Engagement Model in an Italian Cohort of People Living With HIV 148
Long term follow-up of Nevirapine-treated patients in a single centre cohort 147
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 146
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 146
Mortality in patients with early- or late-onset candidaemia 146
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 145
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 144
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 144
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 143
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 143
Detection of HLA-B*57:01 by real-time PCR: implementation into routine clinical practice and additional validation data 143
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 143
Hospital reengineering against COVID-19 outbreak: 1-month experience of an Italian tertiary care center 142
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 141
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 141
Totale 19.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 155.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 155.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.014 0 132 44 183 81 65 100 382 81 161 310 475
2022/20235.312 667 752 449 795 475 677 166 404 619 87 160 61
2023/20242.711 105 690 61 318 115 530 129 51 69 82 306 255
2024/20254.989 83 115 471 167 477 199 235 279 734 446 976 807
2025/202613.609 1.947 350 777 1.610 2.295 1.280 2.096 614 801 1.015 443 381
2026/20271.790 574 1.216 0 0 0 0 0 0 0 0 0 0
Totale 38.001